Theravance Biopharma, Inc.

By person

34 insiders · 82 transactions

28.0×

Rick E Winningham holds 28.0 times base salary in stock. $29.36M of shares against $1.05M in salary for 2025.

Salary from the company's own proxy. The shares are what Rick E Winningham last reported holding, valued at $17.00, the price COM was last bought or sold at on the open market here, on 1 Jul 2026.

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

Samaha Eli

10% owner

$20.92M (3)

$5.79M (3)

+$15.12M

9,174,453

$155.98M

+30.8%

Shafer Bradford J

EVP, Gen. Counsel, Secretary

—

$2.71M (8)

−$2.71M

277,831

$4.72M

+37.5%

Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRS

—

$1.89M (24) scheduled

−$1.89M

226,790

$3.86M

−29.1%

BROSHY ERAN

Director

—

$1.66M (5) scheduled

−$1.66M

44,703

$760.00K

−17.2%

GALA RENEE D

SVP, Chief Financial Officer

—

$1.41M (4)

−$1.41M

157,657

$2.68M

−32.8%

HAUMANN BRETT K

Chief Medical Officer

—

$898.21K (3)

−$898.21K

242,499

$4.12M

+28.8%

MALKIEL BURTON G

Director

$760.21K (3)

—

+$760.21K

115,589

$1.97M

+335.0%

WORBOYS PHILIP D

SVP, RESEARCH & TRANSL SCIENCE

—

$743.06K (4)

−$743.06K

330,752

$5.62M

+82.3%

Hindman Andrew A.

SVP, CHIEF FINANCIAL OFFICER

—

$716.24K (1)

−$716.24K

384,714

$6.54M

+5,951%

GRAHAM RICHARD A

SVP, RESEARCH & DEVELOPMENT

—

$592.92K (14)

−$592.92K

314,915

$5.35M

+182.8%

Winningham Rick E

CHIEF EXECUTIVE OFFICER

$245.00K (1)

$559.50K (1)

−$314.50K

1,726,989

$29.36M

+93.3%

HEGDE SHARATHCHANDRA S

SVP, Research

—

$223.17K (2)

−$223.17K

259,900

$4.42M

+49.8%

Fore Henrietta

Director

$143.93K (1)

—

+$143.93K

24,000

$408.03K

+100.0%

PASQUALONE FRANK

SVP, CHIEF BUSINESS OFFICER

$105.36K (1)

—

+$105.36K

429,783

$7.31M

+90.8%

WHITESIDES GEORGE M

Director

$98.76K (1)

—

+$98.76K

249,076

$4.23M

+9.7%

O'Connor Donal

Director

—

$81.83K (2)

−$81.83K

80,213

$1.36M

+791.3%

SABESAN VIJAY

SVP, TECHNICAL OPERATIONS

—

$21.60K (1)

−$21.60K

235,524

$4.00M

+49.0%

PITZER KENNETH R

SVP, PROD STRAT & COMM PLNG

—

380,123

$6.46M

+130.2%

Grimaud Brett A.

SVP, GEN COUNSEL AND SECRETARY

—

355,168

$6.04M

+47.0%

Sawaf Aziz

SVP & CHIEF FINANCIAL OFFICER

—

336,841

$5.73M

+64.7%

LEE JUNNING

Sr. VP, Technical Operations

—

234,071

$3.98M

−5.4%

Miller Aine

SVP, DEV & HEAD OF IRE OFFICE

—

189,826

$3.23M

+30.6%

BRADY ANN

PRESIDENT, TBIL

—

110,319

$1.88M

+42.6%

MITCHELL DEAN J

Director

—

97,213

$1.65M

+710.1%

SULIMAN SHEHNAAZ

SVP, Corp Dev & Strategy

—

97,198

$1.65M

+5,515%

Smaldone Alsup Laurie

Director

—

80,989

$1.38M

—

Gunderson Robert V JR

Director

—

78,940

$1.34M

+97.8%

YOUNG WILLIAM D

Director

—

78,010

$1.33M

+167.9%

PAKIANATHAN DEEPIKA

Director

—

64,074

$1.09M

—

Molineaux Susan

Director

—

51,034

$867.64K

+325.3%

GRAY SUSANNAH

Director

—

48,146

$818.54K

—

RINGROSE PETER S

Director

—

37,999

$646.03K

+146.3%

Grant Jeremy T

Director

—

32,954

$560.26K

—

GSK plc entity

Former 10% Owner

—

$0.00

−100.0%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Theravance Biopharma, Inc.

By person

Individual transactions

What was left out